ASH: Roche Looks To Fixed-Duration Edge In Bispecifics Battle

Roche is highlighting the fixed-duration dosing benefits of Lunsumio and Columvi over AbbVie/Genmab’s Epkinly in B-cell lymphomas as they fight for market dominance. However, the speed at which the companies complete Phase III studies could also be a deciding factor.

Roche_Logo_Glass

Roche is looking to Phase III clinical trial results to show its Lunsumio and Columvi are the best new bispecific therapies in B-cell lymphomas, and is also highlighting patient convenience and economics as it tries to get ahead of AbbVie/Genmab’s rival CD20XCD3-targeting bispecific, Epkinly.

The company is emphasizing the benefits of its approach of using a fixed duration of treatment with Lunsumio (mosunetuzumab) in...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from ASH

Sweden’s Mendus Clears Regulatory Path For Vididencel Registration Trial

 
• By 

Following promising Phase II data presented at ASH on the company's allogenic leukemia-derived dendritic cell vaccine, Mendus has secured support from the FDA and the EMA for pivotal studies starting later this year.

ASH: AbbVie/Genmab Look To Stake Anti-CD20 Bispecific Claim In CLL

 

Data presented at the ASH conference showed high overall response and complete response rates in heavily pretreated CLL patients with Epkinly.

ASH: How Should BCMA-Directed Bispecifics Fit Into Myeloma Treatment?

 

With two products on the market, a third on the way and a fourth under development too, the question becomes how they will fit in relative to each other and also CAR-T cell therapies.

ASH: Out With The Old, In With The New As BMS Ushers In CELMoD Class

 

BMS presented Phase I/II data for its next-generation small molecule drugs mezigdomide and iberdomide at ASH.

More from Therapy Areas

GSK’s Blenrep US Setback Could Go From Bad To Worse

 

With a US approval any time soon now looking unlikely, analysts are revising Blenrep’s peak sales guidance downwards.

Boehringer Ingelheim Expects Two Key Approvals In Second Half Of 2025

 

The privately held German pharma firm is hoping to bring a new generation of pulmonary fibrosis and cancer drugs to market but their commercial success is not yet a certainty.

More Pressure on Elevidys As The EU’s CHMP Says ‘No’

 

Just days after Roche stopped shipments of the DMD gene therapy following safety concerns raised by two patient deaths, its EU approval application has hit a block.